Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Otitis externa treatment can lead to yeast overgrowth, study finds
“It was most gratifying to be able to confirm our previous observations by use of semi-quantitative cultures” – Ross Bond.
Antibiotic use led to increases in Malassezia pachydermatis.

Scientists are advising veterinary surgeons to monitor for yeast overgrowth in patients that are treated with antibiotics for otitis externa, following a new study.

Although the findings of the research were expected, the phenomenon had not previously been well described in veterinary literature.

Researchers at the Royal Veterinary College (RVC) studied 29 dogs treated with fluoroquinolone or piperacillin-tazobactam for bacterial otitis externa. The dogs were mostly referred with chronic otitis externa after unsuccessful treatment using licensed products.

Ear swabs were taken before and after treatment for cytological evaluation and semi-quantitative culture.

Although bacteria counts significantly decreased after treatment, otic yeast increased, especially Malassezia pachydermatis. This outcome was more common in cases treated with piperacillin-tazobactam.

The researchers believe that increases in yeast were seen because of the antibacterial treatment suppressing bacteria that normally compete with yeast growth and inhibit it.

Further research is needed to find out if antifungal drugs or antiseptic ear rinses can be used to prevent fungal growth when antibiotics are used to treat otitis externa.

Ross Bond, professor of veterinary dermatology at RVC and corresponding author of the study, said: “We are very grateful to BSAVA PetSavers for kindly funding this study and to the owners of the dogs for agreeing to participate.

“It was most gratifying to be able to confirm our previous observations by use of semi-quantitative cultures.

“Our next goal is to find treatment protocols that prevent the fungal dysbiosis without compromising the efficacy of the antibacterial therapy in these very difficult ear cases.”

The study has been published in the Journal of Small Animal Practice.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Strangles survey seeks views of horse owners

News Story 1
 With Strangles Awareness Week just around the corner (5-11 May), vets are being encouraged to share a survey about the disease with their horse-owning clients.

The survey, which has been designed by Dechra, aims to raise awareness of Strangles and promote best practices to prevent its transmission. It includes questions about horse owners' experiences of strangles, together with preventative measures and vaccination.

Respondents to the survey will be entered into a prize draw to win two VIP tickets to Your Horse Live 2025. To access the survey, click here 

Click here for more...
News Shorts
DAERA to reduce BVD 'grace period'

DAERA has reminded herd keepers of an upcoming reduction to the 'grace period' to avoid BVD herd restrictions.

From 1 May 2025, herd keepers will have seven days to cull any BVD positive or inconclusive animals to avoid restrictions being applied to their herd.

It follows legislation introduced on 1 February, as DAERA introduces herd movement restrictions through a phased approach. Herd keepers originally had 28 days to cull BVD positive or inconclusive animals.

DAERA says that, providing herd keepers use the seven-day grace period, no herds should be restricted within the first year of these measures.

Additional measures, which will target herds with animals over 30 days old that haven't been tested for BVD, will be introduced from 1 June 2025.

More information is available on the DAERA website.